ArticleExperimental brain research2026
LC-MS-based metabolomics reveals the In Vivo effects of cognitive formula 1 in rats with Aβ-induced Alzheimer's disease.
Article in Experimental brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive impairment of cognition, behavior, and functional abilities that can ultimately lead to death. Cognitive Formula 1 (CF1), a traditional Chinese medicine (TCM) formulation, has demonstrated promising therapeutic efficacy in clinical applications. However, the precise mechanisms underlying its therapeutic effects in AD remain unclear. An AD rat model was established by intracerebral injection of amyloid-β peptide 1-42 (Aβ₁₋₄₂) to investigate the mechanism of CF1. The results indicated that synergistic interactions among multiple CF1 components influence host metabolic pathways, in particular those involved in glycerophospholipid and amino acid metabolism, thereby suggesting an explanation for the alleviation of systemic metabolic dysregulation by the formulation. CF1 also remodeled the gut microbiota by reducing the abundance of potentially detrimental bacteria, such as Veillonella and Lachnoclostridium, while enhancing that of beneficial bacteria, such as Roseburia. These changes improved intestinal homeostasis, reduced endotoxin influx, and alleviated systemic inflammation. The concurrent improvements in host metabolism and gut microbial composition prevented peripheral pro-inflammatory and oxidative stress signals from reaching the brain, thus inhibiting overactivation of hippocampal microglia and attenuating neuroinflammation. These effects preserved neuronal structure and function, ultimately enhancing learning, memory, and spatial cognition in AD model rats.
Indexed as
Identifiers
42635815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.